Keytruda® (pembrolizumab) – New indications
May 18, 2017 – The FDA announced the approval of Merck’s Keytruda (pembrolizumab) injection, for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) who are not eligible for cisplatin-containing chemotherapy, and for the treatment of patients with locally advanced or metastatic UC who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
Top